ATNX

Oraxol with pembrolizumab

Solid Tumors

Phase 1 Expansion Enrollment

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Oraxol with pembrolizumab for Solid Tumors Phase 1 Expansion Enrollment

  • NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1 data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD

PRIOR DATA
PRESS RELEASES


MECHANISM OF ACTION

  • P-glycoprotein (P-gp) is an active transport protein on the surface of the gastrointestinal (GI) tract. Many anticancer drugs are substrates of P-gp, and when orally administered, they will be pumped back into the GI tract, thereby limiting the drugs to intravenous administration. Encequidar, as a selective and potent P-gp inhibitor, has the potential to allow oral delivery of these chemotherapy agents. Current clinical trials are underway globally with encequidar combined with paclitaxel, docetaxel, irinotecan, eribulin, and topotecan.

  • Encequidar is a novel compound with inhibitory activity specific to P-gp. Encequidar’s distinguishing feature is its minimal oral absorption. This feature localizes P-gp inhibitory activity in the GI tract, improving the absorption of chemotherapy agents, but limiting the potential for unnecessary P-gp inhibition at other places in the body.

  • We believe the Orascovery approach will establish a new paradigm in the use of oral anticancer drugs.

Updated by MV

#ATNX #Oraxol #pembrolizumab #SolidTumors #cancer

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

ATNX - Athenex, Inc. Reports T...

Summary: FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and Februar...

ATNX - Athenex, Inc. to Report...

#ATNX "announced that it will release third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time...

Will ATNX stock price pop if O...

ATNX's oraxol has shown some pretty good data in metastatic breast cancer. And oral paclitaxel vs. IV paclitaxel seems to have some patient convenience advantage. However, the stock has not responded ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon